Irbesartan and emodin on myocardial remodeling in Goldblatt hypertensive rats.
OBJECTIVE
Interactions between the renin-angiotensin system and transforming growth factor-beta 1 (TGF-β1) have been well documented. The aim was to explore the effect of irbesartan combining with emodin on myocardial remodeling in Goldblatt (2K-1C) hypertensive rats.


METHODS
All 60 Sprague-Dawley rats were randomly divided into 5 groups as follows: the sham-clipped without any drugs; 2K-1C without any drugs; the 2K-1C with irbesartan (50 mg/kg/day); the 2K-1C with emodin (80 mg/Kg/day); and the 2K-1C with irbesartan and emodin together for the last 8 weeks of a 12-week period of study. The outcome measures included left ventricular mass index, TGF-β1 and angiotensin II in the left ventricle, mRNA expression of TGF-β1, and connective tissue growth factor (CTGF).


RESULTS
Compared with 2K1C group, the 2K1C/irbesartan group and 2K-1C/emodin plus irbesartan group had significantly lower systolic blood pressure and local angiotensin II (P < 0.05). The left ventricular mass index in each of the 3 treatment groups was significantly lower than that in the 2K1C group, especially in the combined group. The mRNA/protein TGF-β1 and the mRNA CTGF of 2K1C/irbesartan group, 2K1C/emodin group, and 2K-1C/emodin plus irbesartan group were significantly decreased compared with 2K-1C group (P < 0.05).


CONCLUSIONS
Irbesartan or emodin or 2 drugs together can inhibit myocardial remodeling in renovascular hypertension rats probably by reducing TGF-β1 and CTGF expression. The combination of irbesartan and emodin is better than single drug application.
Department of Cardiovascular disease, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China.
Can
C
Chen
Zheng
Z
Liang
Qiang
Q
Chen
Zhi-Gen
ZG
Li
D000804:Angiotensin II / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D055513:Connective Tissue Growth Factor / Q000235:genetics; D004359:Drug Therapy, Combination; D004642:Emodin / Q000008:administration & dosage / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D053773:Transforming Growth Factor beta1 / Q000235:genetics; D020257:Ventricular Remodeling / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D012333:RNA, Messenger; D013777:Tetrazoles; D053773:Transforming Growth Factor beta1; D000804:Angiotensin II; D055513:Connective Tissue Growth Factor; D000077405:Irbesartan; D004642:Emodin